Join The Discussion

 

Two from Fort Worth appointed by Gov. Abbott to university boards

Steve Hicks, a University of Texas System regent who has been a vocal opponent of regents who have criticized the system’s flagship campus in Austin, was reappointed to the board by Gov. Greg Abbott on Thursday. 

read more >

Fort Worth draws closer to deal with Lancaster developer

City staff are planning to introduce the developer Feb. 3 at a meeting of the City Council's Housing and Economic Development Committee.

read more >

Compass BBVA names Happel CEO for Fort Worth

BBVA Compass has appointed Brian Happel, most recently the Fort Worth city president, its chief executive officer of Fort Worth.

read more >

Energy Transfer Partners, Regency Energy announce $18B merger

Energy Transfer Partners LP of Dallas and Regency Energy Partners LP have entered into a definitive merger agreement.

read more >

Museum District: Area’s evolution creating more interaction, public spaces

Fifteen years ago if someone had shot a cannon from Fort Worth’s world-renowned museum district, nobody would have noticed, joked Lori Eklund, senior deputy director of the Amon Carter Museum of American Art. But that has changed.

read more >

 

Nicox, with Fort Worth operations, to acquire Aciex Therapeutics of Boston

Nicox S.A., an international ophthalmic company whose United States operations are based in Fort Worth, will acquire Aciex Therapeutics Inc., a private ophthalmic development pharmaceutical company in Boston, on a cash-free, debt-free basis through a reverse triangular merger.
Under terms of the proposed acquisition, Aciex shareholders will receive an upfront payment of $65 million in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights giving right to shares for a potential additional value of up to $55 million.


The transaction will broaden and strengthen Nicox’s therapeutic development pipeline, which would include two phase 3 candidates, one being developed by Nicox’s partner Bausch + Lomb.
Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including one for allergic conjunctivitis.
Aciex was founded in 2007 with technology licensed from Afferent Therapeutics LLC, a spin-out from Ora Inc.


The completion of the acquisition is subject to the approval of Nicox’s shareholders and other customary conditions.
Nicox was founded in 1996 and is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets, and an expanding international presence through partners. The company had a market cap of $271 million as of Feb. 28, 2014, and cash position of $86.1 million as of Sept. 30, 2013. Nicox employs about 134 people worldwide.
Nicox S.A. is listed on Euronext Paris.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Catch
How 'bout them Cowboys?